NEW YORK – Kura Oncology reported positive interim data from its ongoing Phase II trial of its lead drug candidate, tipifarnib, in the treatment of angioimmunoblastic T-cell lymphoma (AITL). The results from the trial were presented at the American Society of Hematology (ASH) Annual meeting in Orlando on Sunday.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.